Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Relapse

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,167 result(s) found for: Relapse. Displaying page 11 of 159.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    EudraCT Number: 2011-002689-19 Sponsor Protocol Number: Allo-Relapse-2011 Start Date*: 2011-11-22
    Sponsor Name: [...]
    1.
    2. Haukeland University Hospital
    Full Title: TREATMENT OF RELAPSED ACUTE LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: DISEASE STABILIZATION THROUGH CHEMOTHERAPY, IMMUNOMODULATORY TREATMENT AND IMMUNOTHERAPY
    Medical condition: Allotransplanted patients with early acute leukemia repse (within 1 year after transplant)
    Disease:
    Population Age: Adults Gender:
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001079-22 Sponsor Protocol Number: ABR57022 Start Date*: 2024-07-22
    Sponsor Name:University Medical Center Groningen
    Full Title: A multicenter randomized placebo controlled treatment study of leflunomide in polymyalgia rheumatica
    Medical condition: Polymyalgia Rheumatica
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000516-22 Sponsor Protocol Number: 800MS301 Start Date*: 2019-07-08
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3- Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 ...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PT (Not Authorised) EE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003362-41 Sponsor Protocol Number: Leuk-CTL-001 Start Date*: 2020-09-23
    Sponsor Name:FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
    Full Title: Phase I/IIa clinical trial on the safety and preliminary efficacy of donor-derived anti-leukemia cytotoxic T lymphocytes for the prevention of leukemia relapse in children given haploidentical hema...
    Medical condition: Leukemia relapse prevention given haploidentical hematopoietic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001700-21 Sponsor Protocol Number: 20130320 Start Date*: 2015-02-19
    Sponsor Name:Amgen Inc.
    Full Title: An Open-Label, Multi-center, Expanded Access Protocol of Blinatumomab for the Treatment of Pediatric and Adolescent Subjects with Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia...
    Medical condition: Pediatric and Adolescent Subjects with Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    20.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    20.0 100000004864 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-020515-37 Sponsor Protocol Number: CFTY720D2399 Start Date*: 2010-08-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A single arm, open-label, multicenter study evaluating the long-term, safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multip...
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) PT (Completed) CZ (Completed) ES (Completed) SK (Completed) HU (Completed) GB (Completed) SE (Completed) FR (Completed) EE (Completed) IT (Completed) AT (Completed) GR (Completed) NL (Completed) IE (Completed) BE (Completed) DK (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2012-005086-12 Sponsor Protocol Number: GAM-27 Start Date*: 2013-07-05
    Sponsor Name:Octapharma AG
    Full Title: Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis.
    Medical condition: relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) HU (Completed) DE (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006931-11 Sponsor Protocol Number: CPKC412A2114 Start Date*: 2009-11-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of twice daily oral midostaurin and to evaluate the preliminary clinical and pharmacodynami...
    Medical condition: in pediatric patients with relapsed or refractory leukemia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10000835 Acute leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) SE (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000917-30 Sponsor Protocol Number: 101MS207 Start Date*: 2014-11-25
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Open-Label Immunogenicity and Safety Study of subcutaneous Natalizumab 300 mg administered to Subjects with Relapsing Multiple Sclerosis
    Medical condition: Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004425-13 Sponsor Protocol Number: PP01 Start Date*: 2016-01-22
    Sponsor Name:Skåne University Hospital, Department of Oncology
    Full Title: Prospective evaluation of 68-Ga-PSMA-PET and early PSA kinetics during salvage radiotherapy for personalizing the management of men with relapse of prostate cancer after radical prostatectomy.
    Medical condition: Patients with prostate cancer, with a PSA recurrence of ˃ 0.2 ng/ml after prostatectomy, and who are going to receive radiotherapy to the prostate bed.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10066489 Progression of prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005894-36 Sponsor Protocol Number: ZonMw61200014/Nabi4508 Start Date*: 2009-04-27
    Sponsor Name:ZonMw [...]
    1. ZonMw
    2. nabi biopharmaceuticals
    Full Title: A Phase 2B, Multi-Center, Randomized, Double-Blinded, Parallel-Arm Study to Assess Efficacy and Safety of 3’-aminomethylnicotine-P. aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX®) or placebo,...
    Medical condition: Smoking: Subjects must be smoking an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 mont...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053325 Smoking cessation therapy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004323-37 Sponsor Protocol Number: BOS-IIG-01 Start Date*: 2015-03-24
    Sponsor Name:Fundación PETHEMA para el tratamiento de la leucemia y el linfoma
    Full Title: Single nucleotide polymorphism association with response and toxic effects in patients with Ph+ CP-CML treated with bosutinib after relapse or intolerance to previous treatment.
    Medical condition: Patients with chromosome Philadelphia positive (Ph+) in chronic phase mielogenus leukemia (CP CML)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10034877 Philadelphia chromosome positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002236-15 Sponsor Protocol Number: 22407 Start Date*: 2008-07-16
    Sponsor Name:Academic Medical Center
    Full Title: A phase II study in patients with fludarabine refractory CLL: Dasatinib treatment combination for Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
    Medical condition: Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003948 B-Lymphocytic, CLL (Kiel Classification) refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010951-28 Sponsor Protocol Number: CLTR0308-205 Start Date*: 2009-09-30
    Sponsor Name:Celator Pharmaceuticals, Inc
    Full Title: Phase IIB, multicenter, randomized, open-label trial of CPX-351 (Cytarabine:Daunorubicin) liposome injection versus intensive salvage therapy in adult patients ≤ 60 years old with AML in first rela...
    Medical condition: Acute myeloid leukemia recurrent (Acute Myeloid Leukemia in First Relapse Following an Initial CR >1 Month Duration).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10060558 Acute myeloid leukemia recurrent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003205-10 Sponsor Protocol Number: 12072 Start Date*: 2012-09-17
    Sponsor Name:University of Nottingham
    Full Title: A randomised placebo controlled trial of follow on Rifaximin for the prevention of relapse of Clostridium difficile associated diarrhoea.
    Medical condition: C.Difficile antibiotic-associated diarrhoeal infection
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000294-78 Sponsor Protocol Number: CTP001H Start Date*: 2019-06-07
    Sponsor Name:Nektr Technologies
    Full Title: A Randomized, Single-Blinded, Comparative Study of Mycosinate and Curanail in the Treatment of Fungal Nail Infection
    Medical condition: Onychomycosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001911-38 Sponsor Protocol Number: GELTAMOMAN2 Start Date*: 2014-09-19
    Sponsor Name:Grupo Español de Linfoma y Trasplante Autólogo de Médula ósea
    Full Title: AN OPEN MULTICENTER PHASE II STUDY OF EFFICACY AND TOXICITY OF MAINTENANCE SUBCUTANEOUS RITUXIMAB AFTER RESCUE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA NON-ELIGIBLE FO...
    Medical condition: PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA NON-ELIGIBLE FOR AUTO OR ALLO STEM CELL TRANSPLANTATION
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026803 Mantle cell lymphoma stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002048-29 Sponsor Protocol Number: RGH-MD-06 Start Date*: 2012-03-29
    Sponsor Name:Forest Research Institute, Inc
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group study of cariprazine (RGH-188) in the prevention of relapse in patients with schizophrenia
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2004-004349-16 Sponsor Protocol Number: Start Date*: 2005-11-18
    Sponsor Name:GELA Group
    Full Title: Targeted Intensification by a new preparative regimen for patients with Low-Grade B-Cell Lymphoma utilizing standard dose Ytrium 90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy (RIT) combined ...
    Medical condition: Low grade B-cell lymphoma CD20 positive: -Marginal zone -Lymphocytic -Follicular
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021166-30 Sponsor Protocol Number: 2010-SS-Canakinumab Start Date*: 2010-11-25
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Efficacy and safety of canakinumab in Schnitzler syndrome
    Medical condition: Schnitzler syndrome is an acquired autoinflammatory syndrome characterized by urticaria and monoclonal gammopathy, accompanied by intermittent fever, arthralgia or arthritis, bone pain and lymphade...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 08 06:33:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA